Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: Rationale and design of the STEMI-DTU randomized pivotal trial
- PMID: 36058253
- DOI: 10.1016/j.ahj.2022.08.011
Primary left ventricular unloading with delayed reperfusion in patients with anterior ST-elevation myocardial infarction: Rationale and design of the STEMI-DTU randomized pivotal trial
Abstract
Background: Despite successful primary percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI), myocardial salvage is often suboptimal, resulting in large infarct size and increased rates of heart failure and mortality. Unloading of the left ventricle (LV) before primary PCI may reduce infarct size and improve prognosis.
Study design and objectives: STEMI-DTU (NCT03947619) is a prospective, randomized, multicenter trial designed to compare mechanical LV unloading with the Impella CP device for 30 minutes prior to primary PCI to primary PCI alone without LV unloading. The trial aims to enroll approximately 668 subjects, with a potential sample size adaptation, with anterior STEMI with a primary end point of infarct size as a percent of LV mass evaluated by cardiac magnetic resonance at 3-5 days after PCI. The key secondary efficacy end point is a hierarchical composite of the 1-year rates of cardiovascular mortality, cardiogenic shock ≥24 hours after PCI, use of a surgical left ventricular assist device or heart transplant, heart failure, intra-cardiac defibrillator or chronic resynchronization therapy placement, and infarct size at 3 to 5 days post-PCI. The key secondary safety end point is Impella CP-related major bleeding or major vascular complications within 30 days. Clinical follow-up is planned for 5 years.
Conclusions: STEMI-DTU is a large-scale, prospective, randomized trial evaluating whether mechanical unloading of the LV by the Impella CP prior to primary PCI reduces infarct size and improves prognosis in patients with STEMI compared to primary PCI alone without LV unloading.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Conflict of interest Dr Kapur has received research support from Abiomed, Cardiac Assist, and Maquet. and consulting fees/speaker honoraria from Abiomed, Cardiac Assist, Heartware, Maquet, and Thoratec. Dr Kim is a consultant for Abiomed. Dr Stone reports institutional research grants or contracts from Abbott, Bioventrix, Cardiovascular Systems Inc, Phillips, Biosense-Webster, Shockwave, Vascular Dynamics and V-wave; consulting fees from Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Abiomed, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Reva, Shockwave, V-Wave, Cardiomech, Gore, and Vascular Dynamics; honoraria from Cook and Infraredx; and Stock (Equity) in Ancora, Cagent, Applied Therapeutics, Biostar Family of Funds, Spectra Wave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and MedFocus Family of Funds. Drs Ben-Yehuda and Redfors and Ms. Issever report institutional research contracts with Abiomed (no direct compensation). Dr Josephy and Dr Polak are employees of Abiomed. Dr O'Neill is a consultant to Abiomed, Boston Scientific, and Medtronic.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous